The polypill concept

Heart

Volumn 96, Issue 1, 2010, Pages 257-260

  Wald, Nicholas J ^a   Wald, David S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEART MUSCLE ISCHEMIA; HUMAN; PILL; PRIORITY JOURNAL; RISK REDUCTION; STROKE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; OFF LABEL DRUG USE; PRESCRIPTION; RISK FACTOR;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; HUMANS; PATIENT SELECTION; RISK ASSESSMENT;

EID: 77953739687     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.186429     Document Type: Editorial

References (31)

1. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-23
2. Pyorala K, De Backer G, Graham I, et al, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:1300-31
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
4. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10
5. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society Guidelines: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Human Hypertension 2004;18:139-85
6. Chobanian AV, Bakris GL, Black HR, et al, the National High Blood Pressire Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560-72
7. The National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care: partial update. London: Royal College of Physicians, 2006. http://www. nice.org.uk/nicemedia/pdf/HypertensionGuide.pdf
8. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74
9. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch Intern Med 1992;152:56-64
10. Law MR, Wald NJ, Wu T, et al. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994;308:363-6
11. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360: 1903-13
12. Prospective Studies Collaboration. Blood cholesterol and vasacular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-39
13. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-7
14. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427-31
15. Law M, Wald N. Cholesterol, statins, and mortality. Lancet 2008;371:1161-2
16. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high risk individuals; a randomised placebo controlled study. Lancet 2002;360:23-33
18. The EURopean trial on reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-88
19. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ 1999;319:1562-5
20. Wald NJ, Law M, Watt H, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994;343:75-9
21. Law M, Wald NJ, Morris J. Lowering blood pressure to prevent myocardial infarction and strokes: a new preventive strategy. Health Technol Assess 2003;7, No 31
22. Wald N. Folic acid and the prevention of neural tube defects. Maternal nutrition and pregnancy outcome. In: Keen CL, Bendich A, Willhite CC, eds. Ann N Y Acad Sci 1993;678:112-29
23. European patent specification. Formulation for the prevention of cardiovascular disease. EP 1 272 220 B1. Proprietors Wald NJ, Law MR; priority 10.04.2000
24. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
25. Calhoun DA, Lacourciere Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009;54:32-9
26. Bonaa KH, Njolstad I, Ueland PM, et al, for the NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88
27. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1566-77
28. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007;369:1876-82
29. The Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009. doi:10.1016/S0140-6736(09)60611-5
30. Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J 2006;27:1651-6.
31. Wald DS, Law MR, Wald NJ. Polypill prevention programme. http://www.wolfson.qmul.ac.uk/polypill/ audit.html.